Sara A. Hurvitz, MD, FACP, discusses the mechanism of action of evorpacept and data with the agent in pretreated HER2-positive metastatic breast cancer.
Investigating Evorpacept-Based Combinations in HER2+ Breast Cancer
Biomarker analyses indicate that CD47 expression may help predict benefit from zanidatamab plus evorpacept in HER2-positive metastatic breast cancer.
Advertisement
Advertisement